Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Open accessThe DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Abstract
: 1. After 50 years of antipsychotic drug development focused on the dopamine D2 receptor, schizophrenia remains a chronic, disabling disorder for most affected individuals. 2. Studies over the last decade demonstrate that administration of low doses of NMDA receptor antagonists can cause in normal subjects the negative symptoms, cognitive impairments and physiologic disturbances observed in schizophrenia. 3. Furthermore, a number of recently identified risk genes for schizophrenia affect NMDA receptor function or glutamatergic neurotransmission. 4. Placebo-controlled trials with agents that directly or indirectly activate the glycine modulatory site on the NMDA receptor have shown reduction in negative symptoms, improvement in cognition and in some cases reduction in positive symptoms in schizophrenic patients receiving concurrent antipsychotic medications. 5. Thus, hypofunction of the NMDA receptor, possibly on critical GABAergic inter-neurons, may contribute to the pathophysiology of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The prefrontal cortex (PFC) and hippocampus stand out as major regions affected in schizophrenia”
From Adolescent Onset of Cortical Disinhibition in Schizophrenia: Insights From Animal Models (2011) · cites this paper as [3]
In the citing paper
“A loss of scaffolding proteins in spines could alter glutamatergic receptor signaling, disruption of which is theorized to contribute to the etiology of schizophrenia60.”
From Dendritic spine pathology in neuropsychiatric disorders (2011) · cites this paper as [60]
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1×
“Existing drugs are poorly tolerated and exhibit little differences in efficacy (Lieberman et al., 2005).”
BackgroundKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 2×
“Newcomer et al. (1999) extended the findings of Krystal et al. (1994) by showing that declarative memory, the form impaired in schizophrenia, was quite sensitive to low dose ketamine infusion.”
BackgroundRecent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · cited 1×
“Based upon the emerging pharmacology of the NMDAR, Javitt and Zukin (1991) proposed that the psychotomimetic effects of PCP were due to blockade of the NMDA receptors.”
BackgroundTripartite synapses: glia, the unacknowledged partner
Araque, A., Parpura, V., Sanzgiri, R. P., & Haydon, P. G. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01349-6 · Cited by 2,529 · cited 1×
“The glutamatergic synapse consists of a tight functional relationship among the presynaptic terminal, the postsynaptic spine and the ensheathing astrocyte end-foot (Araque et al., 1999; Coyle et al., 2002).”
BackgroundSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
The hippocampal-VTA loop: controlling the entry of information into long-term memory
Lisman, J. E., & Grace, A. A. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.002 · Cited by 1,983
Braff, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,705
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · cited 2×
“In addition, clozapine treatment has been associated with reduction in the rate of suicide, reduction in smoking and reduction in abuse of other substances in schizophrenic patients (Drake et al., 2000; Meltzer et al., 2003; Zimmet et al., 2000).”
BackgroundLesion of striatal neurons with kainic acid provides a model for Huntington's chorea
COYLE, J. T., & SCHWARCZ, R. (1976) · Nature · doi:10.1038/263244a0 · Cited by 1,248 · cited 1×
“We focused on glutamatergic signal transduction before there was any evidence that it could be relevant to neuropsychiatric disorders (Coyle and Schwarcz, 1976).”
BackgroundSelf-citation
Research works printed but not linked: 1
- Wang, X., He, G., Gu, N., Yang, J., Tang, J., Chen, Q., et al. (2004). Association of G72/G30 with schizophrenia in the Chinese population. Biochem. Biophys. Res. Commun.319:1281–1286. [DOI] [PubMed] [Google Scholar] · DOI
Cited by
Items 301–400 of 954
Vostrikov, V., & Uranova, N. (2011) · Schizophrenia Research and Treatment · doi:10.1155/2011/174689 · Cited by 51
“Excess release of glutamate was found in schizophrenia patients [77] and especially in schizophrenic patients with cognitive impairment and negative symptoms [78].”
BackgroundMolecular cause and functional impact of altered synaptic lipid signaling due to a prg‐1 gene SNP
Vogt, J., Yang, J., Mobascher, A., Cheng, J., Li, Y., Liu, X., Baumgart, J., Thalman, C., Kirischuk, S., Unichenko, P., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505677 · Cited by 54
“In sum, our study thus provides a translational line of evidence showing that alterations in E/I balance and pre-attentive stimulus processing, which are considered biomarkers/endophenotypes of psychiatric disorders (Coyle, 2006; Javitt et al, 2008, 2011) and are present in PRG-1 carriers, result from a reduced PRG-1…”
InfluentialThe glycine transport inhibitor sarcosine is an inhibitory glycine receptor agonist
Zhang, H. X., Lyons-Warren, A., & Thio, L. L. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.07.019 · Cited by 49
“Enhanced inhibition may be helpful because γ-aminobutyric acidA receptor (GABAAR) function may be reduced in schizophrenia (Coyle, 2006).”
BackgroundOhi, K., Sumiyoshi, C., Fujino, H., Yasuda, Y., Yamamori, H., Fujimoto, M., Sumiyoshi, T., & Hashimoto, R. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00293 · Cited by 51
Serotonin and Glutamate Interactions in Preclinical Schizophrenia Models
Shah, U. H., & González‐Maeso, J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00044 · Cited by 55
Hall, J., Whalley, H. C., Moorhead, T. W. J., Baig, B. J., McIntosh, A. M., Job, D. E., Owens, D. G. C., Lawrie, S. M., & Johnstone, E. C. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.009 · Cited by 53
Brown, J. W., Whitehead, C. A., Basso, A. M., Rueter, L. E., & Zhang, M. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000739 · Cited by 53
Proton Magnetic Resonance Spectroscopy in 22q11 Deletion Syndrome
da Silva Alves, F., Boot, E., Schmitz, N., Nederveen, A., Vorstman, J., Lavini, C., Pouwels, P., de Haan, L., Linszen, D., & van Amelsvoort, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021685 · Cited by 51
Dauvermann, M. R., Whalley, H. C., Romaniuk, L., Valton, V., Owens, D. G. C., Johnstone, E. C., Lawrie, S. M., & Moorhead, T. W. J. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.01.063 · Cited by 49
“The N-methyl-Daspartate (NMDA) receptor hypofunction model for schizophrenia proposes that altered glutamatergic modulation may underlie the pathophysiology of the disorder (Coyle, 2006; Coyle et al., 2011; Javitt, 2010).”
BackgroundTurnock‐Jones, J. J., Jennings, C. A., Robbins, M. J., Cluderay, J. E., Cilia, J., Reid, J. L., Taylor, A., Jones, D. N. C., Emson, P. C., & Southam, E. (2009) · Synapse · doi:10.1002/syn.20665 · Cited by 49
Huang, M., Felix, A. R., Flood, D. G., Bhuvaneswaran, C., Hilt, D. C., Koenig, G., & Meltzer, H. Y. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3596-0 · Cited by 52
Li, B., Devidze, N., Barengolts, D., Prostak, N., Sphicas, E., Apicella, A. J., Malinow, R., & Emamian, E. S. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2109-09.2009 · Cited by 48
“Third, several studies suggest that enhancing NMDAR function can alleviate schizophrenic symptoms (Matsui et al., 1995; Tsai et al., 1998; Javitt, 2004; Millan, 2005; Coyle, 2006) (but see Tuominen et al., 2005).”
BackgroundRole of glutamate in schizophrenia: integrating excitatory avenues of research
Sodhi, M., Wood, K. H., & Meador-Woodruff, J. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.9.1389 · Cited by 48
Pu, W., Luo, Q., Palaniyappan, L. K., Xue, Z., Yao, S., Feng, J., & Liu, Z. (2016) · Psychological Medicine · doi:10.1017/s0033291715002755 · Cited by 48
“Working memory (WM) deficit, a core feature of cognitive impairment in schizophrenia, appears to be a persistent phenomenon that is closely related to poor long-term outcome (Coyle, 2006; Minzenberg & Carter, 2012), but is often resistant to anti-psychotic drugs (MacDonald & Schulz, 2009).”
BackgroundLi, B.-J., Liu, P., Chu, Z., Shang, Y., Huan, M., Dang, Y., & Gao, C. (2017) · Neuroreport · doi:10.1097/wnr.0000000000000775 · Cited by 49
Memantine in neurological disorders – schizophrenia and depression
Czarnecka, K., Chuchmacz, J., Wójtowicz, P., & Szymański, P. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01982-z · Cited by 49
Singer, P., Feldon, J., & Yee, B. K. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1568-6 · Cited by 51
“…in the comparison between DBA/2 and C57BL/6 mice whether the former would exhibit pharmacologically induced phenotypes that are in keeping with the dopamine and glutamate/N-methyl-D-aspartic acid (NMDA) hypotheses of schizophrenia (c.f. Coyle 2006; Carlsson 1988; Javitt 2007; Snyder 1976).”
BackgroundMcNally, J. M., McCarley, R. W., & Brown, R. E. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-012-0346-z · Cited by 47
Demontis, D., Nyegaard, M., Buttenschøn, H. N., Hedemand, A., Pedersen, C. B., Grove, J., Flint, T. J., Nordentoft, M., Werge, T., Hougaard, D. M., et al. (2011) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31234 · Cited by 44
Neurobiological Background for the Development of New Drugs in Schizophrenia
Lopez-Munoz, F. J., & Álamo, C. (2011) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318215c2f7 · Cited by 54
Farokhnia, M., Sabzabadi, M., Pourmahmoud, H., Khodaie-Ardakani, M.-R., Hosseini, S.-M.-R., Yekehtaz, H., Tabrizi, M. H., Rezaei, F., Salehi, B., & Akhondzadeh, S. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3261-z · Cited by 49
“On the other hand, the glutamatergic hypothesis of schizophrenia provides accountability for both positive and negative symptoms as well as neurocognitive deficits (Coyle 2006; Laruelle et al. 2005).”
Lee, M. J., Jayathilake, K., Dai, J., & Meltzer, H. Y. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.07.013 · Cited by 48
“, 2006), which may contribute to hypoglutamatergic function (Coyle, 2006) and diminished α-7 nicotinic receptor stimulation (Freedman et al.”
BackgroundBlundell, J., Kaeser, P. S., Südhof, T. C., & Powell, C. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0328-10.2010 · Cited by 44
“…synapse function has been implicated in schizophrenia (Carlsson et al., 1999, 2004; Lipska and Weinberger, 2000; Mechri et al., 2001; Coyle et al., 2003; Moghaddam and Jackson, 2003; Weinberger, 2005; Coyle, 2006; Javitt, 2007; Stone et al., 2007; Paz et al., 2008; Sodhi et al., 2008).”
BackgroundAnti-NMDA-Rezeptor-Enzephalitis: Ein interdisziplinäres Krankheitsbild
Prüß, H., Dalmau, J. O., Arolt, V., & Wandinger, K.-P. (2010) · Der Nervenarzt · doi:10.1007/s00115-009-2908-9 · Cited by 50
Wong, P., Sze, Y., Chang, C. C. R., Lee, J., & Zhang, X. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.21 · Cited by 48
Kaşer, M., Soltész, F., Lawrence, P., Miller, S. L., Dodds, C., Croft, R. J., Dudas, R. B., Zaman, R., Fernández-Egea, E., Müller, U., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083255 · Cited by 49
“On the other hand, dysfunctional glutamatergic transmission has been suggested to have more significant role in pathophysiology of cognitive impairments in schizophrenia [58].”
BackgroundMoy, S. S., Ghashghaei, H. T., Nonneman, R. J., Weimer, J. M., Yokota, Y., Lee, D., Lai, C., Threadgill, D. W., & Anton, E. S. (2009) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-009-9017-8 · Cited by 47
“Disease pathology has been associated with an intrinsic state of NMDAR hypofunction [6, 23, 27, 37, 49].”
BackgroundBhandari, A., Voineskos, D., Daskalakis, Z. J., Rajji, T. K., & Blumberger, D. M. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00045 · Cited by 50
The Synapse as a Central Target for Neurodevelopmental Susceptibility to Pesticides
Vester, A. I., & Caudle, W. M. (2016) · Toxics · doi:10.3390/toxics4030018 · Cited by 49
“synaptic puncta, neurite outgrowth, synaptogenesis [56,102] Altered MAPK, PI3K/Akt, estrogen receptor pathways [94] Incr.”
BackgroundEndophenotypes in Schizophrenia: Digging Deeper to Identify Genetic Mechanisms
Greenwood, T. A., Shutes‐David, A., & Tsuang, D. W. (2019) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20190005 · Cited by 55
Feng, Y. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9693-x · Cited by 47
“In addition, glutamatergic and GABAergic dysregulation are also key components in psychiatric diseases, which are tightly connected to the dopaminergic dysfunction circuitry [3, 78, 79 ].”
BackgroundNeurofunctional correlates of glutamate and GABA imbalance in psychosis: A systematic review
Zahid, U., Onwordi, E. C., Hedges, E. P., Wall, M. B., Modinos, G., Murray, R. M., & Egerton, A. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.105010 · Cited by 46
“Glutamatergic dysfunction and N-methyl-D-aspartate (NMDA) receptor hypofunction is implicated in the pathophysiology of schizophrenia (Coyle, 2006; McCutcheon et al., 2020; Egerton et al., 2020).”
BackgroundHoriguchi, M., Hannaway, K. E., Adelekun, A. E., Jayathilake, K., & Meltzer, H. Y. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.64 · Cited by 49
“Hypoglutamatergic activity has been postulated to be a major cause of the cognitive impairment in schizophrenia (CIS; Goldman-Rakic and Selemon, 1997; Coyle, 2006).”
BackgroundZamberletti, E., Viganò, D., Guidali, C., Rubino, T., & Parolaro, D. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001185 · Cited by 49
“The aetiology of schizophrenia has been largely demonstrated as an involvement of the dopaminergic and glutamatergic systems (Coyle, 2006 ; Howes & Kapur, 2009) but recent experimental evidence strongly suggest that alterations in the endocannabinoid system may also contribute to the pathogenesis…”
BackgroundFoss‐Feig, J. H., McPartland, J. C., Anticevic, A., & Wolf, J. M. (2015) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-015-2539-x · Cited by 45
“With regard to underlying genetics and neurobiology, while many have proposed common pathways and neural abnormalities in schizophrenia (Coyle 2006; Krystal et al. 2003; Uhlhaas and Singer 2010), it is also likely there are at least some more specific or localized differences in brain development and functioning drivi…”
Schultz, C. C., Nenadić, I., Koch, K., Wagner, G., Roebel, M., Schachtzabel, C., Mühleisen, T. W., Nöthen, M. M., Cichon, S., Deufel, T., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.56 · Cited by 45
“Genetic findings of the recent years fundamentally broadened our knowledge of schizophrenia (O`Donovan et al, 2009) and particularly in view of the glutamatergic system as several identified genes are implicated to interact with the glutamatergic neurotransmission (Coyle, 2006).”
BackgroundAkhondzadeh, S., Ghayyoumi, R., Rezaei, F., Salehi, B., Modabbernia, A., Maroufi, A., Esfandiari, G.-R., Naderi, M., Ghebleh, F., Tabrizi, M. H., et al. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2044-z · Cited by 44
“Theories bridging the dopamine and the NMDA hypotheses of schizophrenia into one conceptual framework argue that dopamine activity is under the control of NMDA inhibitory receptors (Akhondzadeh 1998; Noorbala et al. 1999; Laruelle et al. 2003; Carlsson et al. 2004; Coyle 2006).”
BackgroundCellular and circuit models of increased resting-state network gamma activity in schizophrenia
White, R. S., & Siegel, S. J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.11.011 · Cited by 47
Quercetin Reduces Cortical GABAergic Transmission and Alleviates MK-801-Induced Hyperactivity
Fan, H.-R., Du, W., Zhu, T., Wu, Y., Liu, Y., Wang, Q., Wang, Q., Gu, X., Shan, X., Deng, S., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.07.031 · Cited by 46
“The finding [37] that the psychotomimetic drug phencyclidine noncompetitively blocked the N-methyl-D-aspartate receptor (NMDAR) gave rise to the glutamate theory of schizophrenia [10, 11, 26], according to which NMDAR hypofunction and disturbances in NMDAR-related gene expression and metabolic pathways confer the dise…”
BackgroundBodkin, J. A., Coleman, M. J., Godfrey, L., Carvalho, C. M. B., Morgan, C. J., Suckow, R. F., Anderson, T., Öngür, D., Kaufman, M. J., Lewandowski, K. E., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.04.031 · Cited by 45
“(44-47) The GLDC triplication seemed fortuitously amenable to a treatment intervention tailored to normalizing the biology hypothesized to be affected by the mutation.”
BackgroundSelf-citationMöhler, H., Rudolph, U., Boison, D., Singer, P., Feldon, J., & Yee, B. K. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.03.003 · Cited by 44
“The latter is consistent with the glutamate hypothesis of schizophrenia (Goff and Coyle, 2001; Tsai and Coyle, 2002; Coyle and Tsai, 2004; Coyle, 2006) and current findings regarding GlyT1 inhibition or deletion (Lindsley et al., 2006).”
ResultMorin Pretreatment Attenuates Schizophrenia-Like Behaviors in Experimental Animal Models
Ben‐Azu, B., Aderibigbe, A. O., Omogbiya, I. A., Ajayi, A. M., & Iwalewa, E. O. (2017) · Drug Research · doi:10.1055/s-0043-119127 · Cited by 43
“Preclinical and clinical data have shown that negative symptoms have been recognized as a major feature of schizophrenia [21, 26].”
BackgroundInfluentialImpaired conscious access and abnormal attentional amplification in schizophrenia
Berkovitch, L., Del Cul, A., Maheu, M., & Dehaene, S. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.03.010 · Cited by 39
“Importantly, resolving this issue may also provide a test of theories of dysfunctional N-methyl-D-aspartate (NMDA) transmission in schizophrenia (Berkovitch et al., 2017; Coyle, 2006; Jentsch and Roth, 1999; Olney and Farber, 1995; Stephan et al., 2009).”
InfluentialĆurĉić‐Blake, B., Bais, L., Sibeijn‐Kuiper, A., Pijnenborg, H. M., Knegtering, H., Liemburg, E. J., & Aleman, A. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.05.020 · Cited by 44
“The dysfunction or blockade of glutamate receptors, specifically the N-methyl-D-aspartate (NMDA) receptors, by neurochemical compounds such as ketamine can cause schizophrenia-like symptoms including AVH (Coyle, 2006; Krystal et al., 1994; Lahti et al., 1995).”
Markov, V., Krug, A., Krach, S., Whitney, C., Eggermann, T., Zerres, K., Stöcker, T., Shah, N. J., Nöthen, M. M., Treutlein, J., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.05.067 · Cited by 45
“…studies have reported decreased dysbindin 1 expression in schizophrenia-related brain regions, such as the hippocampus, dorsolateral prefrontal cortex (DLPFC) and midbrain, amongst other regions (Weickert et al., 2004; Numakawa et al., 2004; Talbot et al., 2004; Coyle, 2006; Weickert et al., 2008).”
BackgroundDysregulation of glutamate carboxypeptidase II in psychiatric disease
Guilarte, T. R., Hammoud, D. A., McGlothan, J. L., Caffo, B. S., Foss, C. A., Kozikowski, A. P., & Pomper, M. G. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.11.013 · Cited by 46
“Another site at which NAAG can affect glutamatergic synapses is its action as an N-methyl-D-aspartate (NMDA) receptor antagonist (Coyle, 2004), (Coyle, 2006).”
BackgroundAuditory hallucinations: Expectation–perception model
Nazimek, J. M., Hunter, M. D., & Woodruff, P. W. R. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.03.014 · Cited by 41
Snigdha, S., Idris, N. F., Grayson, B., Shahid, M., & Neill, J. C. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2091-5 · Cited by 45
“Based on findings from animal and human studies, hypoglutamatergic function, particularly in the frontal cortex, has been proposed to be a relevant factor contributing to cognitive impairment in schizophrenia (Coyle 2006; Jentsch and Roth 1999; Lieberman et al, 2008).”
BackgroundMethodHoriguchi, M., Hannaway, K. E., Adelekun, A. E., Huang, M., Jayathilake, K., & Meltzer, H. Y. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.09.030 · Cited by 43
Balanced translocation linked to psychiatric disorder, glutamate, and cortical structure/function
Thomson, P. A., Duff, B. J., Blackwood, D., Romaniuk, L., Watson, A., Whalley, H. C., Li, X., Dauvermann, M. R., Moorhead, T. W. J., Bois, C., et al. (2016) · Schizophrenia · doi:10.1038/npjschz.2016.24 · Cited by 43
Spreng, R. N., DuPré, E., Ji, J. L., Yang, G., Diehl, C., Murray, J. D., Pearlson, G. D., & Anticevic, A. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz064 · Cited by 44
The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter
Lowe, J. A., III, Hou, X., Schmidt, C. J., Tingley, F. D., McHardy, S., Kalman, M., DeNinno, S. L., Sanner, M. A., Ward, K. M., Lebel, L. A., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.04.035 · Cited by 41
Myles‐Worsley, M., Tiobech, J., Browning, S. R., Korn, J., Goodman, S. J., Gentile, K. L., Melhem, N., Byerley, W., Faraone, S. V., & Middleton, F. A. (2013) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32125 · Cited by 42
Snyder, M. A., Adelman, A. E., & Gao, W. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.180 · Cited by 45
“It should be pointed out that our finding of enhanced NMDAR function in juvenile MAM animals contrasts with the NMDAR hypofunction associated with SZ in adulthood (Coyle, 2006; Dracheva et al, 2001; Javitt, 2004; Moghaddam and Jackson, 2003; Mohn et al, 1999; Olney et al, 1999; Tamminga, 1999).”
BackgroundLi, X., Wang, L.-B., Xiong, Y., Bo, Q., He, F., Li, F., Hou, W., Wen, Y., Wang, X., Yang, N., et al. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112608 · Cited by 41
Genetic overlap and causal associations between smoking behaviours and mental health
Barkhuizen, W., Dudbridge, F., & Ronald, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-93962-7 · Cited by 43
Neurotrophins in Mesial Temporal Lobe Epilepsy With and Without Psychiatric Comorbidities
Kandratavicius, L., Monteiro, M. R., Assirati, J. A., Carlotti, C. G., Hallak, J. E., & Leite, J. P. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000002 · Cited by 40
Rolls, E. T. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.017 · Cited by 39
Proline Metabolism in Neurological and Psychiatric Disorders
Yao, Y., & Han, W. (2022) · Molecules and Cells · doi:10.14348/molcells.2022.0115 · Cited by 40
“In patients, postmortem studies revealed a significant reduction in GABA levels in the prefrontal cortex, a reduced number of GAD67-expressing neurons that coexpress NR2A in the prefrontal cortex, and reduced activity of glutamate carboxypeptidase II in the frontal cortex, hippocampus, and temporal cortex (Coyle, 2006…”
Kremeyer, B., Valencia, J. G., Kymäläinen, H., Wratten, N. S., Chavarriaga, G. J. R., Palacio, C., Miranda, A., López‐Jaramillo, C., Restrepo, M., Bedoya, G., et al. (2008) · Human Heredity · doi:10.1159/000181154 · Cited by 46
“This region harbours several candidate genes for schizophrenia, including the Regulator of G Protein Signalling 4 ( RGS4 ), the Nitric Oxide Synthase 1 (neuronal) Adaptor Protein ( NOS1AP ; also called CAPON ), and the U2AF Homology Motif Kinase 1 ( UHMK1 ). The NOS1AP gene is of particular interest due to its involve…”
BackgroundAssociative learning and the genetics of schizophrenia
Hall, J., Romaniuk, L., McIntosh, A. M., Steele, J. D., Johnstone, E. C., & Lawrie, S. M. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.01.011 · Cited by 48
Sex-based differences in gene expression in hippocampus following postnatal lead exposure
Schneider, J. S., Anderson, D. W., Sonnenahalli, H., & Vadigepalli, R. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.08.008 · Cited by 37
“Abnormal N-methyl-D-aspartate receptor (NMDAR) function has long been associated with developmental lead exposure and has also been implicated in a variety of cognitive disorders including the pathophysiology of schizophrenia (Coyle 2006).”
BackgroundMeade, A. J., Meloni, B. P., Cross, J., Bakker, A. J., Fear, M. W., Mastaglia, F. L., Watt, P. M., & Knuckey, N. W. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06459.x · Cited by 40
Torres, E. R. S., Akinyeke, T., Stagaman, K., Duvoisin, R. M., Meshul, C. K., Sharpton, T. J., & Raber, J. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00140 · Cited by 38
“L-glutamate, the major excitatory neurotransmitter (Coyle, 2006), activates both ionotropic and metabotropic glutamate receptors (mGlu).”
BackgroundDeutsch, S. I., & Burket, J. A. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110017 · Cited by 41
Ishola, I. O., Ben‐Azu, B., Adebayo, O. A., Ajayi, A. M., Omorodion, I. L., Edje, K. E., & Adeyemi, O. O. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.10.007 · Cited by 39
Santini, M. A., Ratner, C., Aznar, S., Klein, A. B., Knudsen, G. M., & Mikkelsen, J. D. (2013) · Journal of Neuroscience Research · doi:10.1002/jnr.23198 · Cited by 38
Metabotropic Glutamate Receptors for New Treatments in Schizophrenia
Herman, E. J., Bubser, M., Conn, P. J., & Jones, C. K. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_11 · Cited by 42
Ketamine as Antidepressant? Current State and Future Perspectives
Hasselmann, H. (2013) · Current Neuropharmacology · doi:10.2174/1570159x113119990043 · Cited by 43
“In general, negative and cognitive hallmarks of psychosis seem most sensitive to ketamine [168].”
BackgroundEffects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models
Socała, K., Nieoczym, D., Rundfeldt, C., & Właź, P. (2010) · Pharmacological Reports · doi:10.1016/s1734-1140(10)70279-6 · Cited by 37
“Numerous studies indicate that non-competitive antagonists of NMDA receptors (phencyclidine and ketamine) induce psychotomimetic effects, both in humans and in animals, which resemble symptoms of schizophrenia [3, 4, 9].”
BackgroundUnderstanding taurine CNS activity using alternative zebrafish models
Mezzomo, N. J., Fontana, B. D., Kalueff, A. V., Barcellos, L. J. G., & Rosemberg, D. B. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.09.008 · Cited by 38
“Given the role of NMDA receptors in the reward circuitry and in substance dependence, it is reasonable to link a dysfunction of the NMDA receptor dysfunction with schizophrenia (Coyle et al., 2002; Coyle and Tsai, 2004; Coyle 2006).”
BackgroundSacchi, S., Cappelletti, P., & Murtas, G. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00055 · Cited by 37
“This represents a molecular mechanism that could explain many symptomatic features of schizophrenia (Coyle et al., 2003; Coyle, 2006; Stone and Pilowsky, 2007; Pollegioni and Sacchi, 2010).”
BackgroundParker, J. G., Beutler, L. R., & Palmiter, R. D. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2411-11.2011 · Cited by 36
“Although we report here that attenuating NMDAR signaling within the PFC disrupts associative learning, NMDAR hypofunction (Mohn et al., 1999; Coyle, 2006), particularly within this brain region (Akbarian et al., 1996), has been hypothesized to contribute to many of the symptoms observed in…”
BackgroundPsychiatric phenomena as initial manifestation of encephalitis by anti‐NMDAR antibodies
Maat, P., de Graaff, E., van Beveren, N. J. M., Hulsenboom, E., Verdijk, R. M., Koorengevel, K. M., VanDuijn, M. M., Hooijkaas, H., Hoogenraad, C. C., & Smitt, P. A. E. S. (2012) · Acta Neuropsychiatrica · doi:10.1111/acn.12013 · Cited by 46
“Moreover, there is evidence that in the schizophrenia syndrome altered activity of the NMDAR on GABA interneurons in the prefrontal cortex plays a role (27).”
BackgroundRodrigues, T. B., Granado, N., Ortiz, O., Cerdán, S., & Moratalla, R. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21302 · Cited by 37
Zhang, Q., Yu, Y., & Huang, X. (2016) · Scientific Reports · doi:10.1038/srep19581 · Cited by 42
“Considering the clinical relevance of PCP-induced schizophrenia-like behaviors in humans and rodents 10,11 , our study may provide insights into the mechanism underlining olanzap-ine’s effect on neurite outgrowth and synaptic protein expressions.”
Ben‐Azu, B., Adebayo, O. G., Fokoua, A. R., Oritsemuelebi, B., Chidebe, E. O., Nwogueze, B. C., Kumanwee, L., Uyere, G. E., & Emuakpeje, M. T. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2023.12.008 · Cited by 37
“…striatal pathways as well as 5-HT 2A/C -release of serotonin induce large proportion of the positive and negative symptoms, thus necessitating the search for drugs with D 2 -5-HT 2A/C antagonism capacities in the treatment of the disease (Coyle, 2006; Chatterjee et al., 2012; Ben-Azu et al., 2021).”
BackgroundYohn, S. E., Harvey, P. D., Brannan, S. K., & Horan, W. P. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1421554 · Cited by 40
“NMDA receptor hypofunction is a convergence point for the development and diverse symptoms of schizophrenia, especially cognitive de fi cits (43, 44).”
BackgroundGLT‐1 upregulation impairs prepulse inhibition of the startle reflex in adult rats
Bellesi, M., Melone, M., Gubbini, A., Battistacci, S., & Conti, F. (2009) · Glia · doi:10.1002/glia.20798 · Cited by 36
Kirby, B. P., Waddington, J. L., & O’Tuathaigh, C. M. P. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.09.010 · Cited by 38
Beste, C., Baune, B. T., Domschke, K., Falkenstein, M., & Konrad, C. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.04.022 · Cited by 36
“Moreover, glutamatergic neural transmission is affected in these diseases (Coyle, 2006; Beal and Ferrante, 2004), which may also modulate these cognitive processes.”
BackgroundHowes, O. D., Bonoldi, I., McCutcheon, R. A., Azis, M., Antoniades, M., Bossong, M. G., Modinos, G., Pérez, J. M., Stone, J. M., Santangelo, B., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0541-2 · Cited by 39
Chopra, M., Yao, Y., Blake, T. J. A., Hampson, D. R., & Johnson, E. C. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.152553 · Cited by 36
“Several studies have linked mGluR3 to the pathophysiology of schizophrenia (Coyle, 2006) through candidate gene association studies (Addington et al.”
BackgroundTreadmill exercise enhances NMDA receptor expression in schizophrenia mice
Park, J.-K., Lee, S., & Kim, T. (2014) · Journal of Exercise Rehabilitation · doi:10.12965/jer.140088 · Cited by 37
“According to the Coyle (2006), there is new evidence to suspect that the abnormality in NMDA receptor function may contribute to schizophrenia’s symptoms that are resistant to antipsychotic medication.”
BackgroundComputational Neuropsychiatry – Schizophrenia as a Cognitive Brain Network Disorder
Dauvermann, M. R., Whalley, H. C., Schmidt, A., Lee, G. L., Romaniuk, L., Roberts, N., Johnstone, E. C., Lawrie, S. M., & Moorhead, T. W. J. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00030 · Cited by 43
Phosphodiesterase 10 inhibitors in clinical development for CNS disorders
Geerts, H., Spiros, Ä., & Roberts, P. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1268531 · Cited by 39
Homer1a protein expression in schizophrenia, bipolar disorder, and major depression
Leber, S. L., Llenos, I. C., Miller, C. L., Dulay, J. R., Haybaeck, J., & Weis, S. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1776-x · Cited by 37
Walker, A. G., & Conn, P. J. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.003 · Cited by 35
“These observations, as well as extensive preclinical research, have led to the hypothesis that NMDA receptor hypofunction can play a role in the pathophysiology underlying schizophrenia [4,5].”
BackgroundDysfunctional d-aspartate metabolism in BTBR mouse model of idiopathic autism
Nuzzo, T., Sekine, M., Punzo, D., Miroballo, M., Katane, M., Saitoh, Y., Galbusera, A., Pasqualetti, M., Errico, F., Gozzi, A., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140531 · Cited by 36
“, schizophrenia) and sharing symptoms with ASD, including cognitive and social interaction impairments [18-24].”
BackgroundJeon, P., Limongi, R., Ford, S. D., Mackinley, M., Dempster, K., Théberge, J., & Palaniyappan, L. K. (2021) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgaa072 · Cited by 36
“In this study, we tested if (1) glutamate-mediated deficit indexed by ACC MRS measure of glutamate is present in early stages of psychosis, (2) whether this deficit progressively worsens in the first 6 months of treatment, and (3) if patients show an exaggerated longitudinal decline compared to HC.”
BackgroundMethodInfluentialSiegel, J. E., Romaniuk, L., Whalley, H. C., Roberts, N., Branigan, H. P., Stanfield, A. C., Lawrie, S. M., & Dauvermann, M. R. (2021) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2021.111302 · Cited by 39
Behavioral and Molecular Biomarkers in Translational Animal Models for Neuropsychiatric Disorders
Sarnyai, Z., Alsaif, M., Bahn, S., Ernst, A., Guest, P. C., Hradetzky, E., Kluge, W., Stelzhammer, V., & Wesseling, H. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-387718-5.00008-0 · Cited by 36
“Disrupted network connectivity due to abnormal functioning of neurotransmitter systems such as dopamine (DA) and glutamate may serve as a final common pathway for several psychiatric disorders (Meltzer and Stahl, 1976; Coyle, 2006a).”
BackgroundFrattini, L. F., Piubelli, L., Sacchi, S., Molla, G., & Pollegioni, L. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08354.x · Cited by 35
Ma, L., Skoblenick, K., Seamans, J. K., & Everling, S. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1839-15.2015 · Cited by 36
“, 2004; Homayoun and Moghaddam, 2007), the net effect could be disinhibition of pyramidal neurons (Jackson et al., 2004; Coyle, 2006; Skoblenick and Everling, 2012).”
BackgroundBurket, J. A., Cannon, W. R., Jacome, L. F., & Deutsch, S. I. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.08.014 · Cited by 36
Geerts, H., Roberts, P., & Spiros, Ä. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00198 · Cited by 37
“…genetic and neuropathology data and includes a hypodopaminergic cortical D 1 R tone (Durstewitz and Seamans, 2008 ), NMDA-R hypofunction (Coyle, 2006) documented by a hypocortical-hyperstriatal imbalance in metabolic imaging (Meyer-Lindenberg et al., 2002), a GABA deficit (Volk and…”
BackgroundBeyond Dopamine: Glutamate as a Target for Future Antipsychotics
Sendt, K.-V., Giaroli, G., & Tracy, D. K. (2012) · ISRN Pharmacology · doi:10.5402/2012/427267 · Cited by 40
“Dopaminergic dysregulation might thus be the result of primary impairments of glutamate neurotransmission and a subsequent reinforcing factor in maintaining these impairments [75].”
Saleem, A., Qurat-ul-Ain, Q.-U.-A., & Akhtar, M. F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.895668 · Cited by 35
“Another hypothesis indicated that the reduced function of NMDA receptors could produce symptoms of schizophrenia (Moghaddam, 2003; Coyle, 2006).”
BackgroundAnticevic, A., Schleifer, C., & Cho, Y. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.4/aanticevic · Cited by 37
A Case of Anti-NMDA Receptor Encephalitis Treated with ECT
Jones, K. C., Schwartz, A. C., Hermida, A. P., & Kahn, D. A. (2015) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000100 · Cited by 34
Metadata
- Authors
- Coyle, J. T.
- Affiliations
- Harvard University (US)
- Corresponding author
- Coyle, Joseph T.
- ORCID
- Coyle, Joseph T.
- Venue
- Cellular and Molecular Neurobiology
- Published
- 2006-06-14
- Volume
- 26
- Issue
- 4-6
- Pages
- 363-382
- ISSN
- 0272-4340 (ISSN-L)
- 1573-6830
- PMC
- PMC11881825
- OpenAlex
- W2008639041
- Cited by
- 917
- References
- 159
- Citations by year
- 2026: 13 · 2025: 27 · 2024: 16 · 2023: 29 · 2022: 29 · 2021: 28 · 2020: 35 · 2019: 47 · 2018: 43 · 2017: 44 · 2016: 45 · 2015: 56 · 2014: 47 · 2013: 74 · 2012: 62
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cellular and Molecular Neurobiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (P50MH060450, MH P50-60450, MH R01-572901)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- schizophrenia, glutamate, NMDA receptor, dopamine hypothesis, negative symptoms, cognitive impairment, NMDA receptor antagonists, schizophrenia risk genes, GABAergic interneurons, antipsychotic drugs, glutamatergic neurotransmission
- MeSH terms
- Animals, Dopamine, Glutamates, Humans, Models, Biological, Synaptic Transmission, Schizophrenia, Antipsychotic Agents, Receptors, N-Methyl-D-Aspartate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.